Given the low frequency of CLL cases with MYC aberrations, and the low proportion of cells with MYC aberrations (in case of a subclonal abnormality) and thus the requirement for systematic screening with a fluorescent in situ hybridization (FISH) probe, it will be challenging to evaluate the prognostic impact of these two abnormalities in prospective trials of targeted therapies (e.g. BTKi and BCl2 inhibitors). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.